Patents

The following ImmunityBio, Inc. products, platforms and technology are protected by patents in the United States and elsewhere. This website page is provided to satisfy virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act. In accordance with Section 287(a) of Title 35 of the United States Code, notice is given. Additional patents and patent applications may also be pending in the United States and internationally.

Aldoxorubicin, aldoxorubicin combinations, or uses thereof

Application Number Grant Number
CN 201480032023.9
US 14/893,821 US 10,278,981

Anktiva™ (Nogapendekin Alfa Imbakicept; also known as N-803 or Alt-803), Anktiva™ combinations, or uses thereof

Application Number   Grant Number
CN 201410242394.1   CN ZL201410242394.1
CN 201810136797.6
EP 11178091.2   EP 2388266
US 12/700,949   US 8,163,879
US 13/428,776   US 8,940,289
US 15/254,713   US 10,450,359
EP 15162957.3   EP 2918607
US 13/769,179   US 9,255,141
US 13/854,903   US 9,328,159
US 15/083,998   US 10,150,805
US 16/749,967
US 16/749,955   US 11,046,747
EP 15815782.6
EP 20152694.4
US 14/755,989   US 9,925,247
US 15/921,512   US 10,537,615
US 16/444,807
EP 18740021.3
US 16/620,791
US 16/443,560

COVID hAd5 Vaccine Platform or uses thereof

Application Number   Grant Number
US 12/651,836   US 8,298,549

Ganitumab or uses thereof

Application Number Grant Number
US 13/891,781 US 8,895,008

hAd5 (E1-,E2b-) Platform or uses thereof

Application Number   Grant Number
EP 08781241.8   EP 2170384
EP 16153921.8   EP 3061462
US 12/651,836   US 8,298,549
US 13/622,263
US 14/422,504   US 9,605,276
US 15/433,934   US 10,563,224
CN 201680014846.8   CN ZL201680014846.8
EP 16735415.8
EP 16783793.9
US 15/542,005
US 15/564,413
US 16/306,097
US 16/458,726   US 10,874,729
EP 08743578   EP 2125868
US 12/528,796   US 8,188,214
US 16/107,559
EP 16751434.8
US 15/749,214   US 10,550,164
US 16/778,043   US 11,034,740
EP 04814140   EP 1697399
US 13/176,341   US 8,957,192

HIV treatments

Application Number   Grant Number
US 16/749,955   US 11,046,747

Nant Cancer Vaccine Platform or uses thereof

Application Number   Grant Number
US 16/903,882   US 11,000,550
EP 08781241.8   EP 2170384
EP 16153921.8   EP 3061462
US 12/651,836   US 8,298,549
US 14/422,504   US 9,605,276
CN 201680014846.8   CN ZL201680014846.8
US 15/542,005
US 15/564,413
US 14/755,989   US 9,925,247
EP 17821361.7
US 16/312,246
US 16/783,734
US 10/738,646   US 7,465,454
US 12/334,729   US 8,153,136
US 12/643,869   US 8,343,502
US 16/656,293
EP 08743578   EP 2125868
EP 16751434.8
US 16/778,043   US 11,034,740
EP 04814140   EP 1697399

NK-92® Cell Platform, NK-92® combinations, or uses thereof

Application Number   Grant Number
US 10/008,955   US 10,138,462
AU 2013200124   AU 2013200124
AU 2017210556   AU 2017210556
US 11/178,258   US 7,618,817
US 16/940,018
CN 201680019087.4
EP 16773863.2
US 15/529,848   US 10,456,420
US 16/541,847   US 10,736,921
US 16/903,882   US 11,000,550
EP 18740021.3
US 16/620,791
EP 18763512.3
US 15/914,665   US 10,801,013
US 16/424,201   US 10,774,310
EP 18740019.7
US 16/620,855
US 17/056,385
US 16/529,159
US 16/529,251   US 10,765,701
US 16/934,606

Yeast Vaccine Platform or uses thereof

Application Number   Grant Number
US 10/738,646   US 7,465,454
US 12/334,729   US 8,153,136
US 12/335,094   US 8,067,559
US 12/643,869   US 8,343,502
US 15/454,176   US 10,363,294
US 13/803,719   US 9,198,941
US 14/926,372   US 9,623,097
US 16/389,235
US 14/778,118   US 10,507,235